Welcome to our dedicated page for Citius Oncology SEC filings (Ticker: CTOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Citius Oncology, Inc. (Nasdaq: CTOR) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As an emerging growth company incorporated in Delaware and listed on Nasdaq, Citius Oncology reports material corporate events, governance decisions, and securities transactions through forms such as 8‑K, proxy statements, and registration-related documents.
Recent Form 8‑K filings describe events including amendments to the company’s 2024 Omnibus Stock Incentive Plan and unregistered sales of equity securities. For example, Citius Oncology has reported an increase in the number of shares of common stock authorized for issuance under the 2024 Omnibus Stock Incentive Plan and the issuance of warrants to a financial advisor in a private placement. Another 8‑K details stockholder voting results at the 2025 annual meeting, including the election of Class I directors, approval of the incentive plan amendment, and ratification of the independent registered public accounting firm.
The company’s definitive proxy statement on Schedule 14A outlines the agenda and voting procedures for the annual meeting, the proposals presented to stockholders, and information on the number of shares outstanding and entitled to vote. Regulation FD disclosures, such as the posting of an updated corporate presentation, are also reported via Form 8‑K and incorporated by reference.
Through Stock Titan, these filings are organized so that investors can quickly locate specific document types, such as current reports on material events, proxy materials, and other disclosures that complement Citius Oncology’s press releases about LYMPHIR™ (denileukin diftitox-cxdl) and its commercialization. AI-powered tools on the platform can assist users by summarizing lengthy documents, highlighting key items like equity plan changes, warrant issuances, and governance decisions, and helping readers understand how these regulatory filings relate to the company’s broader oncology strategy.
Citius Oncology filed a prospectus supplement registering 6,818,182 shares of common stock underlying existing warrants and 272,727 shares underlying the placement agent’s warrants. The company also disclosed a warrant inducement agreement, a Loan and Security Agreement providing up to $25.0 million of term loans and related lender warrants, and a Third Amendment to a promissory note that permits conversion at $0.90 per share. The New Warrants and related lender and placement agent warrants are exercisable only after Stockholder Approval and the filing and effectiveness of a resale registration statement; exercises are subject to beneficial ownership limits and customary adjustment provisions. The company reported aggregate gross proceeds of approximately $11.5 million from the warrant inducement transaction and expects the debt financing to fund operations per the Loan Agreement.
Citius Oncology, Inc. entered into a warrant inducement transaction and a new senior secured loan to raise capital for LYMPHIR commercialization and general corporate purposes. A healthcare-focused investor agreed to immediately exercise warrants for 12,777,778 shares at $0.90 per share, providing approximately $11.5 million in gross proceeds, and received 25,555,556 new warrants at a $0.90 exercise price.
The company also entered into a Loan and Security Agreement providing up to $25.0 million in term loans, with $10.0 million funded at closing and additional tranches tied to revenue and liquidity milestones. The loans mature on November 1, 2029, carry a minimum annual interest rate of 12.75%, and are secured by substantially all assets. Lenders and agents receive fees, warrants and a conversion option, and a related-party promissory note was amended and subordinated to the new senior debt.
Citius Oncology, Inc. files a prospectus supplement registering 6,818,182 shares of Common Stock underlying the Warrants and 272,727 shares underlying the Placement Agent’s Warrants as part of its Post-Effective Amendment to Registration Statement No. 333-288656. The supplement incorporates Form 8-K disclosures describing positive investigator-initiated Phase 1 topline data for LYMPHIR™ across multiple tumor settings, early U.S. commercial launch traction, and the initial shipment of LYMPHIR to Europe.
The prospectus supplement notes the company’s Common Stock last reported close at $0.92 per share as of May 4, 2026 and includes a Nasdaq notice that the company is below the $1.00 bid-price requirement with a compliance period through October 19, 2026.
Citius Oncology, Inc. announced the initial shipment of its lymphoma therapy LYMPHIR (denileukin diftitox-cxdl) to Europe through a regional distribution partner, expanding access beyond the United States. Eligible patients will obtain the drug via country-specific Named Patient Programs under local regulations.
LYMPHIR is an IL‑2 receptor–directed cytotoxin approved by the FDA for adults with relapsed or refractory Stage I–III cutaneous T‑cell lymphoma after at least one prior systemic therapy and was launched in the U.S. in December 2025. Management estimates the initial market for LYMPHIR exceeds $400 million and is underserved by existing options. The product carries a boxed warning for capillary leak syndrome and other significant risks, including hepatotoxicity and serious infusion-related reactions, underscoring the need for careful monitoring in clinical use.
Citius Oncology, Inc. received a notice from Nasdaq that its common stock has failed to meet the minimum $1.00 per share bid price requirement for the last 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2).
The company has 180 calendar days, until October 19, 2026, to regain compliance. If the stock trades at or above $1.00 for at least ten consecutive business days during this period, Nasdaq will confirm compliance. If compliance is not regained, Citius Oncology may qualify for an additional 180-day period, potentially using a reverse stock split to cure the deficiency.
The Nasdaq notice does not immediately affect trading, and the shares continue to trade on the Nasdaq Capital Market under the symbol CTOR. The company is evaluating options, but there is no assurance it will regain or maintain compliance, and failure could ultimately lead to delisting, subject to appeal rights.
Citius Oncology, Inc. reported an early commercial update on the U.S. launch of LYMPHIR for relapsed or refractory Stage I–III cutaneous T‑cell lymphoma. The company highlighted increasing formulary adoption at leading oncology centers, broad payer coverage progress, and growing repeat orders that support early prescribing momentum.
Citius is also expanding LYMPHIR’s clinical development through investigator-led studies, including use prior to CAR‑T therapy in diffuse large B‑cell lymphoma and in combination with pembrolizumab in solid tumors, both with positive topline data. Management estimates the initial LYMPHIR market currently exceeds $400 million and is underserved by existing therapies.
Citius Oncology, Inc. reported positive topline results from an investigator-initiated Phase 1 trial of LYMPHIR™ (denileukin diftitox-cxdl) combined with pembrolizumab (KEYTRUDA®) in patients with recurrent or refractory gynecologic cancers, including ovarian and endometrial malignancies.
Among 25 evaluable patients, no unexpected safety signals or serious immune-related adverse events were seen at any dose level. In 21 evaluable patients, the trial showed a 24% objective response rate and a 48% clinical benefit rate, defined as complete or partial response or stable disease for at least six months. Full safety and efficacy data are planned for presentation at an international cancer conference.
Citius Oncology, Inc. filed an 8-K to share positive topline Phase 1 data for LYMPHIR given before commercial CD19-directed CAR-T therapy in high-risk relapsed or refractory diffuse large B-cell lymphoma. In 14 treated patients, investigators reported an 86% overall response rate, including 57% complete responses and 29% partial responses.
The investigator-initiated, open-label, dose-escalation study used single doses of LYMPHIR at 5, 7, or 9 µg/kg followed by low-dose chemotherapy and FDA-approved CAR-T products such as Yescarta, Breyanzi, or Kymriah. LYMPHIR was reported as well tolerated with no dose-limiting toxicities. The company notes the Phase 1 trial was not designed or powered to assess clinical efficacy or long-term outcomes.
LYMPHIR is already FDA-approved and commercially available in the U.S. for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy and was launched by Citius Oncology in December 2025. Management estimates the initial market for LYMPHIR exceeds $400 million and is underserved by existing therapies.
Citius Oncology, Inc. is filing a post-effective amendment to its Form S-1 to make available up to 6,818,182 shares of common stock underlying previously issued common warrants and 272,727 shares underlying placement agent warrants.
The offering consists solely of shares issuable upon exercise of outstanding warrants; the company would receive up to approximately $7.9 million if all outstanding warrants are cash‑exercised. The prospectus states the exercise price for the Common Warrant is $1.09 per share and for the Placement Agent Warrant is $1.65 per share. The prospectus notes 95,366,113 shares outstanding after giving effect to full exercise (assumption of full exercise). The company reported a last sale price of $1.21 per share on February 19, 2026. The amendment updates the prospectus for continuous resale under Rule 415 and confirms no new securities are being registered beyond the previously registered warrant‑underlying shares.
Citius Oncology reported that Armistice Capital, LLC and Steven Boyd beneficially own 8,078,404 shares, representing 9.79% of the common stock. The position is held through Armistice Capital Master Fund Ltd., for which Armistice Capital acts as investment manager; the Master Fund disclaims beneficial ownership arising from its lack of voting or dispositive power under the Investment Management Agreement.
The filing is a joint Schedule 13G/A signed by Steven Boyd on February 17, 2026 reporting shared voting and dispositive power over the 8,078,404 shares.